Announced details
Clinical testing, including assessment of iron deficiency and confirmation of hyperferritinemia
Measurement range: 5–2,500 ng/mL
A product manufactured and marketed by our company
Marketing Authorization Notification No.: 09E1X80001000006. Expiration date: Not disclosed
The product is positioned as one of the priority strategic products under Management Plan 2030, but the specific amount of its impact on results is Not disclosed
The company does not address Contract Value / Offering price.
WHO 4th International Standard for Ferritin
| Item | Details |
|---|---|
| Names of Products / Services Covered | LZ Test ‘Eiken’ FERⅡ |
| Relationship with the Company | A product manufactured and marketed by our company |
| Launch date | 31 July 2026 (scheduled launch) |
| Applicable area | Clinical testing, including assessment of iron deficiency and confirmation of hyperferritinemia |
| Registration number and expiry date | Marketing Authorization Notification No.: 09E1X80001000006. Expiration date: Not disclosed |
| Quantitative Effects | Measurement range: 5–2,500 ng/mL |
| Impact on Business Performance | The product is positioned as one of the priority strategic products under Management Plan 2030, but the specific amount of its impact on results is Not disclosed |
| Source | WHO 4th International Standard for Ferritin |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To address needs in clinical testing, including the diagnosis of iron deficiency, by reducing retesting rates for high-concentration specimens, improving testing efficiency and enhancing reproducibility in the low-concentration range. The company also aims to strengthen the profitability of its domestic business and expand sales of high-margin products.